HK Innoen "New GERD Drug 'K-CAB' Launched in Peru"

"Securing a 75 Trillion Won Market in Latin America"

HK inno.N announced on the 16th that its new drug for gastroesophageal reflux disease, 'K-CAB,' was officially launched in Peru on the 12th (local time).

At the 'Ki-CAB' launch symposium held last August at the Westin Lima Hotel in Peru.
[Photo by HK Innoen]

K-CAB (active ingredient: Tegoprazan) is a new drug for gastroesophageal reflux disease belonging to the potassium-competitive acid blocker (P-CAB) class, with the advantage of showing rapid efficacy within 30 minutes after administration. Additionally, it is characterized by proven efficacy and safety even with long-term use up to 6 months.

The product name of K-CAB in Peru is 'Ki-CAB,' and local marketing and distribution are handled by Laboratorios Carnot, a major pharmaceutical company in Latin America. HK inno.N signed an export contract for finished K-CAB tablets with its partner Carnot in 2018, targeting 17 Latin American countries including Peru.

K-CAB has entered a total of 35 overseas countries, including major markets such as the United States, China, and Brazil, through technology transfers or finished product exports. Among these, it has entered 18 countries in Latin America, with two countries including Peru having launched the product. K-CAB was launched in Mexico, the second-largest pharmaceutical market in Latin America, in May of this year.

HK inno.N plans to consecutively apply for approval of K-CAB in major Latin American countries within this year. Through this, the company aims to accelerate its dominance in the Latin American pharmaceutical market, which is worth approximately 75 trillion KRW annually. The company recently completed the approval application for K-CAB in Chile.

Kwok Dal-won, CEO of HK inno.N, said, "K-CAB is rapidly expanding its market worldwide, including Latin America, Southeast Asia, and Asia, enhancing its status as a K-new drug. As approval applications are expected to continue in other countries, we will do our best to help K-CAB become a world-class new drug."

A representative from partner company Carnot stated, "October 12, the launch date of K-CAB, coincides with Columbus Day, the day Columbus set foot on the American continent, making it significant that the new drug for gastroesophageal reflux disease has landed in Peru. We hope K-CAB will become an innovative treatment option in the Latin American pharmaceutical market."

K-CAB recorded a cumulative outpatient prescription performance of 114.1 billion KRW domestically from January to September this year, showing about 19% growth compared to the same period last year. The cumulative prescription performance of K-CAB from 2019 to 2022 is a total of 350.3 billion KRW, maintaining the number one position in the peptic ulcer drug market for four consecutive years since its launch.

Meanwhile, among the total 35 countries where K-CAB has entered overseas markets, it has been launched in seven countries including China, Mongolia, the Philippines, Mexico, Indonesia, Singapore, and Peru.

This content was produced with the assistance of AI translation services.